<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[RoslinCT 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=43804></link><description><![CDATA[RoslinCT 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 05 May 2026 04:36:16 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2023/08/12_31017998_20230818105208_6519220560.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors]]></title><link>https://www.newswire.co.kr/newsRead.php?no=992263</link><description><![CDATA[EDINBURGH, Scotland & BOSTON--(Business Wire/Korea Newswire)--RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.  Professor Sir Peter Mathieson brings an exceptional wealth of experien...]]></description><pubDate>Wed, 26 Jun 2024 12:00:00 +0900</pubDate></item><item><title><![CDATA[RoslinCT, 피터 매디슨 교수와 알렉산더 보스를 신임 비상임 이사로 임명]]></title><link>https://www.newswire.co.kr/newsRead.php?no=992265</link><description><![CDATA[에든버러, 스코틀랜드 & 보스턴--(Business Wire/뉴스와이어)--선도적인 세포 및 유전자 요법 위탁개발생산기관(CDMO)인 RoslinCT는 피터 매디슨(Peter Mathieson) 경(우등 의학 학사 및 외과학 학사(Bachelor of Medicine, Bachelor of Surgery with Honors, MB BS(Hons)), 박사, 왕립 내과 의사 협회 펠로우(Fellow of the Royal College of Physicians, FRCP), 에든버러 왕립 내과 의사 협회 펠로우 (Fellow of the Royal College of ...]]></description><pubDate>Wed, 26 Jun 2024 12:00:00 +0900</pubDate></item><item><title><![CDATA[RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=975564</link><description><![CDATA[EDINBURGH, Scotland & BOSTON--(Business Wire/Korea Newswire)--RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene Therapies, is pleased to announce the appointment of Dean J. Morris as the Chief Operations Officer at their Boston facility. Mr. Morris brings a wealth of experience and expertise in commercial manufacturing operations, process development,...]]></description><pubDate>Wed, 04 Oct 2023 13:35:00 +0900</pubDate></item><item><title><![CDATA[RoslinCT Boston, 최고운영책임자에 Dean J. Morris 임명]]></title><link>https://www.newswire.co.kr/newsRead.php?no=975565</link><description><![CDATA[스코틀랜드, 에딘버러 및 보스턴--(Business Wire/뉴스와이어)--선진 세포 및 유전자 치료를 위한 선도적 개발제조수탁기관(Contract Development And Manufacturing Organization, CDMO)인 RoslinCT는 보스턴 시설에서 Dean J. Morris를 최고운영책임자로 임명하게 됐음을 흔쾌히 발표하고 있다. 모리스 씨는 생물제제, 제약 및 의료 기기 산업 내에서 상업적 제조 운영, 공정 개발, 엔지니어링, 검증 및 품질 기능에 대한 폭넓은 경험과...]]></description><pubDate>Wed, 04 Oct 2023 13:35:00 +0900</pubDate></item><item><title><![CDATA[RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board]]></title><link>https://www.newswire.co.kr/newsRead.php?no=972537</link><description><![CDATA[EDINBURGH, Scotland & BOSTON--(Business Wire/Korea Newswire)--RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB). The SAB is comprised of cell and gene therapy pioneers with extensive experience, providing valuable insight into a range of topics for the dev...]]></description><pubDate>Fri, 18 Aug 2023 11:30:00 +0900</pubDate></item><item><title><![CDATA[로슬린CT, 과학 자문위원회에 데렉 헤이 박사 임명 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=972538</link><description><![CDATA[에든버러, 스코틀랜드--(Business Wire/뉴스와이어)--첨단 세포 및 유전자 치료법을 위한 선도적인 계약 개발 및 제조 조직(contract development and manufacturing organization, CDMO)인 로슬린CT는 데렉 헤이 박사(Dr. Derek Hei)를 과학 자문위원회(Scientific Advisory Board, SAB)에 임명했다고 발표했다. SAB는 광범위한 경험을 보유한 세포 및 유전자 치료법의 선구자들로 구성되며 첨단 치료법의 개발 및 제조를 위한...]]></description><pubDate>Fri, 18 Aug 2023 11:30:00 +0900</pubDate></item></channel></rss>